Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference

HAMILTON, Bermuda, July 18, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, announced today that the company will host a symposium and make four poster  presentations at the 2016 Alzheimer's Association International Conference (AAIC) being held in Toronto July 24-28.

"Our presence at this year's AAIC highlights our progress towards building a leading pipeline of potential treatments for patients with dementia," said Vivek Ramaswamy, CEO of Axovant Sciences. "Over the next 18 months, we expect to report results from all four of our ongoing studies in both Alzheimer's disease and Lewy body dementia. If developed successfully, our pipeline of innovative CNS product candidates will have the opportunity to improve the lives of millions of patients and their families."

During the conference, Axovant is sponsoring a symposium entitled "The Debate Continues: Unraveling the Science of Alzheimer's Disease," featuring two clinical debates involving the following speakers: Lon S. Schneider, MD, Dennis J. Selkoe, MD, Rachelle S. Doody, MD, PhD, Khalid Iqbal, PhD, and Gary Small, MD (moderator).

In addition, Peter Mittler, CBE, PhD, a trained clinical psychologist who has devoted his career to championing the rights of people with intellectual and developmental disabilities to education and citizenship and recently addressed the United Nations regarding dementia treatment as a human rights issue, will deliver a keynote address "Living Well with Dementia: A Fundamental Human Rights Issue."

Symposium
The Debate Continues: Unraveling the Science of Alzheimer's Disease

Date: Wednesday, July 27, 2016             6:00 P.M. – 8:45 P.M. EDT
Location: Fairmont Royal York Hotel
The company will present the following posters:

A Large, Randomized, Double‐Blind, Placebo‐Controlled Study Evaluating Intepirdine (RVT-101), a Neurotransmitter‐Targeted Therapy, in Subjects with Mild‐to‐Moderate Alzheimer's Disease on Donepezil Treatment: Phase 3 MINDSET Study Design

Date: July 27, 2016           9:30 A.M. – 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P4-001

In Vivo Alterations in Brain Glucose Utilization with Intepirdine (RVT-101), a 5-HT₆ Receptor Antagonist for the Treatment of Alzheimer's Disease

Date: July 27, 2016           9:30 A.M. – 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P4-022

Effect of Food on the Pharmacokinetics of Intepirdine (RVT-101) in Healthy Adult Subjects

Date: July 26, 2016           9:30 A.M. – 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P3-014

An Evaluation of the Safety in Human Subjects of Nelotanserin, a Highly Potent and Selective 5‐HT_2A Inverse Agonist Being Developed as a Treatment for Visual Hallucinations and REM Behavior Disorder in Lewy Body Dementia

Date: July 26, 2016           9:30 A.M. – 10:30 A.M. EDT
Location: Metro Toronto Convention Centre Room Hall D/E
Abstract Number: P3-018

About Axovant

Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the condition.

SOURCE Axovant Sciences Ltd.

Related Links

http://www.axovant.com